SEC Form 4 · accession 0001192482-18-000223
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael F Cola
Officer — President and CEO · Director
Period of report
May 14, 2018
Accepted (ET)
May 16, 2018 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F1 | $1.51 | May 14, 2018 | A | 450,000 | A | — | May 14, 2028 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F1The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on May 14, 2019, then in 24 equal monthly installments on the 14th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer.